These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37199321)

  • 1. PD-1/PD-L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-L1 expression level.
    Jin Z; Wang J; Sun J; Zhu C; Zhang J; Zhang B
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1794. PubMed ID: 37199321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.
    Wu HX; Pan YQ; He Y; Wang ZX; Guan WL; Chen YX; Yao YC; Shao NY; Xu RH; Wang F
    J Clin Oncol; 2023 Mar; 41(9):1735-1746. PubMed ID: 36473145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT; Leone AG; Wong NZH; Zhao JJ; Tey JCS; Sundar R; Pietrantonio F
    JAMA Oncol; 2023 Feb; 9(2):215-224. PubMed ID: 36480211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and adverse reactions analysis of PD-1/PD-L1 inhibitors in advanced esophageal squamous cell carcinoma.
    Wang LL; Xie YX; Liu Y
    Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):659-667. PubMed ID: 38305608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and activity of PD-1 blockade in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis with focus on the value of PD-L1 combined positive score.
    Leone AG; Petrelli F; Ghidini A; Raimondi A; Smyth EC; Pietrantonio F
    ESMO Open; 2022 Feb; 7(1):100380. PubMed ID: 35093742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
    Li D; Tang L; Hu J; Cao X; He Y
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
    Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
    ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
    Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
    BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review.
    Yang YL; Li ZQ; Wang QL; Gu JJ; Fang XJ; Huang GH
    Clin Ther; 2021 Nov; 43(11):1997-2012. PubMed ID: 34794831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
    Wang BC; Zhang ZJ; Fu C; Wang C
    Medicine (Baltimore); 2019 Nov; 98(47):e18054. PubMed ID: 31764833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
    Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study.
    Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y
    Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
    J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
    Lee J; Kim B; Jung HA; La Choi Y; Sun JM
    Cancer Immunol Immunother; 2021 May; 70(5):1203-1211. PubMed ID: 33123755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Park S; Oh D; Choi YL; Chi SA; Kim K; Ahn MJ; Sun JM
    Cancer; 2022 Jun; 128(11):2148-2158. PubMed ID: 35319779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.